BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Clinical trials for BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS explained in plain language.
Never miss a new study
Get alerted when new BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS trials appear
Sign up with your email to follow new studies for BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Second chance: Liposome-Wrapped chemo targets tough leukemia
Disease control Recruiting nowThis study is for people with acute myeloid leukemia (AML) whose cancer did not go away after standard chemotherapy. It tests a drug called Vyxeos, which combines two chemotherapy drugs (cytarabine and daunorubicin) inside a tiny fat bubble (liposome) to deliver them more effecti…
Matched conditions: BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 17, 2026 06:50 UTC
-
Experimental drug combo offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a chemotherapy drug called CPX-351 in people with high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) that came back or didn't respond to standard treatment. The main goals are to find the safest dose and check for side…
Matched conditions: BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New hope for rare blood disorder: ruxolitinib trial targets eosinophils
Disease control Recruiting nowThis study tests the drug ruxolitinib in 10 people with hypereosinophilic syndrome or related disorders, where high levels of eosinophils (a type of white blood cell) cause organ damage. The goal is to see if ruxolitinib can lower eosinophil counts and improve symptoms. Participa…
Matched conditions: BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Phase: PHASE2 • Sponsor: William Shomali • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC